ENTEST BIOMEDICAL, INC. (OTCMKTS:ENTB) Files An 8-K Other Events
Item 8.01. Other Events

On October 24, 2017 Zander Therapeutics, Inc. (a subsidiary of Entest BioMedical, Inc. under common control with Entest BioMedical, Inc.) issued an aggregate of 900,000 of its common shares (“Shares”) to three trusts under common control for aggregate consideration of $900,000.

The Shares were issued to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Shares. The proceeds from the sale of the Shares were utilized for general corporate purposes.

Item 9.01. Financial Statements and Exhibits.

EXHIBIT INDEX

10.1 Form of Agreements for sale of Shares.

ENTEST BIOMEDICAL, INC. Exhibit
EX-10.1 2 ex10_1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT     THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Zander Therapeutics,…
To view the full exhibit click here

About ENTEST BIOMEDICAL, INC. (OTCMKTS:ENTB)

Entest BioMedical, Inc. is engaged in the development and commercialization of immunotherapeutic therapies for the veterinary market, as well as the acquisition and operation of veterinary hospitals. The Company is engaged in the development and commercialization of ImenVax, a therapeutic cancer vaccine for use in canines, and the development and commercialization of certain intellectual property for non-human veterinary therapeutic use. Its products include ImenVax I, ImenVax II, ImenVax III and ENT-576. ImenVax I is a therapeutic for canine cancer, which involves isolating tumor cells from the patient and then placing the cells into a cell implant device that is inserted subcutaneously into the patient. ImenVax II is in early-stage of development. ImenVax III is intended to function by harnessing the ability of placental extracts to combat canine cancers. It is developing ENT-576 for the treatment of chronic obstructive pulmonary disease (COPD).